Solasia Pharma K.K.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,092M | ¥617M | ¥316M | ¥429M |
| Gross Profit | ¥662M | ¥337M | ¥185M | ¥207M |
| Operating Income | -¥2,471M | -¥1,139M | -¥1,950M | -¥860M |
| Pretax Income | -¥2,474M | -¥1,135M | -¥1,956M | -¥862M |
| Net Income | -¥2,548M | -¥1,112M | -¥1,941M | -¥876M |
| EPS | -¥16.77 | -¥6.62 | -¥8.90 | -¥3.33 |
| Operating Margin | -226.28% | -184.60% | -617.09% | -200.47% |
| Balance Sheet | ||||
| Total Assets | ¥3,134M | ¥2,229M | ¥1,356M | ¥2,078M |
| Total Equity | ¥2,662M | ¥1,874M | ¥1,035M | ¥1,620M |
| Total Liabilities | ¥472M | ¥355M | ¥321M | ¥458M |
| Cash | ¥803M | ¥728M | ¥875M | ¥1,378M |
| Interest-bearing Debt | ¥37M | ¥60M | ¥12M | ¥16M |
| Equity Ratio | 84.94% | 84.07% | 76.33% | 77.96% |
| D/E Ratio | 0.01 | 0.03 | 0.01 | 0.01 |
| Cash Flow | ||||
| Operating CF | -¥2,074M | -¥359M | -¥1,033M | - |
| Investing CF | -¥418M | - | - | - |
| Financing CF | ¥2,571M | ¥275M | ¥1,180M | - |
| Free CF | -¥2,477M | -¥359M | -¥1,034M | - |
| Efficiency | ||||
| ROE | -95.72% | -59.34% | -187.54% | -54.07% |
| ROA | -81.30% | -49.89% | -143.14% | -42.16% |
Latest IR Information
-
Start of Sales of Epicele in Brazil and Future Revenue Outlook｜July 2026
The start of sales of Epicele in Brazil has been completed, with sales scheduled to begin in Q4 2026. Revenue is reflected in the FY2026 financial statements, and milestone income is also anticipated.
Read more -
Latest Update on Phase Ib/II Clinical Trials of Our Investigational Drug SP-05 (Alorichtoxin-Sulfate)
Read more -
Status of Sancuso (SP-01) Product Sales (Disclosure Items Progress)
Read more
Latest News (5 items)
Company Information
About
Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.
